Long term cell use linked to Brain Tumor Risk

cell-phone-useLong-term use of both mobile and cordless phones is associated with an increased risk for glioma, the most common type of brain tumor, the latest research on the subject concludes.

The new study shows that the risk for glioma was tripled among those using a wireless phone for more than 25 years and that the risk was also greater for those who had started using mobile or cordless phones before age 20 years.

“Doctors should be very concerned by this and discuss precautions with their patients,” study author Lennart Hardell, MD, PhD, professor, Department of Oncology, University Hospital, Örebro, Sweden, told Medscape Medical News.

[Read more…]

New Hope to Improve Resection of Malignant Brain Tumors: Raman Technology

brain-tumorsAn optical technology for discriminating brain tumors from normal brain may eventually help surgeons in the operating room. Also this week: keeping neuronal growth on the straight and narrow.

New Light on Brain Tumors

When patients with brain tumors undergo surgery, it’s hard for surgeons to tell where tumor ends and normal brain starts, which often means cancerous tissue is left behind. But generous margins may compromise brain function.

Now, a technique known as stimulated Raman scattering microscopy has shown better discrimination in preclinical studies, said investigators led by Sunney Xie, PhD, of Harvard University, who hope to develop the technology into a handheld probe to be used in the operating room.

[Read more…]

Treatment of spine and intracranial tumors with dural involvement

Intraoperative 32P High Dose Rate Brachytherapy of the Dura for Recurrent PRIMARY and Metastatic Intracranial and Spine Tumors

Folkert, Michael R. M.D., Ph.D.; Bilsky, Mark H. M.D.; Cohen, Gil’ad N. M.S.; Zaider, Marco Ph.D.; Dauer, Lawrence T. Ph.D.; Cox, Brett W. M.D.; Boland, Patrick J. M.D.; Laufer, Ilya M.D.; Yamada, Yoshiya M.D.

Treatment of spine and intracranial tumors with dural involvement is complicated by radiation tolerance of sensitive structures, especially in the setting of prior treatment. [Read more…]

Current Treatment Strategies for Malignant Gliomas

a report by

Michael Weller

Chairman, Department of Neurology, University Hospital Zurich

Anaplastic astrocytomas, oligoastrocytomas and oligodendrogliomas (World Health Organization (WHO) grade III) and glioblastomas (WHO grade IV) are collectively referred to as malignant gliomas, whereas WHO grade I and II gliomas are designated low-grade gliomas.1 For decades, neurosurgical resection – whenever possible – and post-operative radiotherapy have been the cornerstones of treatment for malignant gliomas. Most chemo­therapeutic agents active in other types of cancer produced little benefit for glioma patients, with the possible exception of nitrosoureas. In contrast, recent years have seen significant advances in the fields of neurosurgical resection, radio-oncological treatment approaches and, most significantly, medical therapy (see Table 1), exemplified by the approval of temozolomide for newly diagnosed glioblastoma.2 [Read more…]